MCID: ESP025
MIFTS: 42

Esophagus Adenocarcinoma

Categories: Cancer diseases

Aliases & Classifications for Esophagus Adenocarcinoma

MalaCards integrated aliases for Esophagus Adenocarcinoma:

Name: Esophagus Adenocarcinoma 12 14
Adenocarcinoma of Esophagus 12 41 69
Oesophageal Adenocarcinoma Nos 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4914
MeSH 41 C562730
NCIt 46 C4025
SNOMED-CT 64 276803003
UMLS 69 C0279628

Summaries for Esophagus Adenocarcinoma

Disease Ontology : 12 An esophageal carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Esophagus Adenocarcinoma, also known as adenocarcinoma of esophagus, is related to barrett esophagus and adenocarcinoma. An important gene associated with Esophagus Adenocarcinoma is CDO1 (Cysteine Dioxygenase Type 1), and among its related pathways/superpathways are MicroRNAs in cancer and Chronic myeloid leukemia. The drugs Menthol and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include testes, liver and colon, and related phenotypes are endocrine/exocrine gland and digestive/alimentary

Related Diseases for Esophagus Adenocarcinoma

Diseases related to Esophagus Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 137)
# Related Disease Score Top Affiliating Genes
1 barrett esophagus 31.6 CDKN2A CDX2 ERBB2 PTGS2 TP53
2 adenocarcinoma 30.2 CDKN2A ERBB2 PTGS2 TP53
3 squamous cell carcinoma 29.4 CDKN2A ERBB2 PTGS2 TP53 WWOX
4 esophageal cancer 28.7 CDKN2A CDX2 ERBB2 PTGS2 TP53 WWOX
5 fungal esophagitis 10.6 ATP12A ATP4A
6 bladder calculus 10.6 ATP12A ATP4A
7 gastrointestinal neuroendocrine benign tumor 10.6 ATP12A ATP4A
8 gastric neuroendocrine neoplasm 10.6 ATP12A ATP4A
9 neonatal candidiasis 10.6 ATP12A ATP4A
10 acute laryngitis 10.6 ATP12A ATP4A
11 gastroduodenal crohn's disease 10.6 ATP12A ATP4A
12 toxic megacolon 10.6 ATP12A ATP4A
13 aspiration pneumonitis 10.6 ATP12A ATP4A
14 gastric antral vascular ectasia 10.6 ATP12A ATP4A
15 esophageal candidiasis 10.6 ATP12A ATP4A
16 postsurgical hypothyroidism 10.6 ATP12A ATP4A
17 rumination disorder 10.5 ATP12A ATP4A
18 laryngeal disease 10.5 ATP12A ATP4A
19 duodenitis 10.5 ATP12A ATP4A
20 congenital disorder of deglycosylation 10.5 ATP12A ATP4A
21 granulomatous gastritis 10.5 ATP12A ATP4A
22 dyskinesia of esophagus 10.5 ATP12A ATP4A
23 ischemic neuropathy 10.5 ATP12A ATP4A
24 anismus 10.5 ATP12A ATP4A
25 capillary disease 10.5 ATP12A ATP4A
26 peptic esophagitis 10.5 ATP12A ATP4A
27 protoplasmic astrocytoma 10.5 PTGS2 TP53
28 duodenal disease 10.5 ATP12A ATP4A
29 hernia, hiatus 10.5 ATP12A ATP4A
30 esophageal atresia/tracheoesophageal fistula 10.5 ATP12A ATP4A
31 laryngitis 10.5 ATP12A ATP4A
32 laryngeal tuberculosis 10.5 ATP12A ATP4A
33 uterine corpus serous adenocarcinoma 10.5 ERBB2 TP53
34 glioma susceptibility 1 10.5 ERBB2 TP53
35 lymphocytic colitis 10.5 ATP12A ATP4A
36 chronic intestinal vascular insufficiency 10.5 ATP12A ATP4A
37 non-proliferative fibrocystic change of the breast 10.5 ERBB2 TP53
38 clostridium difficile colitis 10.5 ATP12A ATP4A
39 brain stem astrocytic neoplasm 10.5 CDKN2A TP53
40 fallopian tube adenocarcinoma 10.4 ERBB2 TP53
41 squamous cell carcinoma of the oropharynx 10.4 CDKN2A TP53
42 lower urinary tract calculus 10.4 ATP12A ATP4A
43 spitz nevus 10.4 CDKN2A TP53
44 diarrhea 1, secretory chloride, congenital 10.4 ATP12A ATP4A
45 keratinizing squamous cell carcinoma 10.4 CDKN2A TP53
46 mucoepidermoid esophageal carcinoma 10.4 TP53 WWOX
47 squamous cell carcinoma of the larynx 10.4 CDKN2A TP53
48 uterine body mixed cancer 10.4 ERBB2 TP53
49 aspiration pneumonia 10.4 ATP12A ATP4A
50 bartholin's gland benign neoplasm 10.4 CDKN2A TP53

Graphical network of the top 20 diseases related to Esophagus Adenocarcinoma:



Diseases related to Esophagus Adenocarcinoma

Symptoms & Phenotypes for Esophagus Adenocarcinoma

MGI Mouse Phenotypes related to Esophagus Adenocarcinoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.96 CDX2 ERBB2 MAP7 PTGS2 ATP4A TP53
2 digestive/alimentary MP:0005381 9.92 CDX1 CDX2 ERBB2 PTGS2 ATP12A ATP4A
3 neoplasm MP:0002006 9.63 CDX2 ERBB2 PTGS2 TP53 CDKN2A WWOX
4 reproductive system MP:0005389 9.56 CDX2 ERBB2 MAP7 PTGS2 TP53 CDKN2A
5 skeleton MP:0005390 9.23 CDX1 CDX2 ERBB2 PTGS2 TP53 CDKN2A

Drugs & Therapeutics for Esophagus Adenocarcinoma

Drugs for Esophagus Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 180)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Menthol Approved Phase 4 2216-51-5 16666
2
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1 51-21-8 3385
3
Irinotecan Approved, Investigational Phase 4,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
4
Levoleucovorin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 68538-85-2
5
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 61825-94-3 43805 6857599 5310940 9887054
6
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 59-30-3 6037
7
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1 58-05-9 143 6006
8
Camptothecin Experimental Phase 4,Phase 2,Phase 1 7689-03-4
9 Liver Extracts Phase 4,Phase 2,Phase 1
10 Antidotes Phase 4,Phase 2,Phase 3,Phase 1
11 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
12 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
13 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
14 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1
15 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
16 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1
17 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1
18 topoisomerase I inhibitors Phase 4,Phase 2,Phase 1
19 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
20 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1
21 Vitamin B Complex Phase 4,Phase 2,Phase 3,Phase 1
22 Vitamins Phase 4,Phase 2,Phase 3,Phase 1
23 Folate Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1
24 Vitamin B9 Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1
25
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
26
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
27
Capecitabine Approved, Investigational Phase 2, Phase 3, Phase 1 154361-50-9 60953
28
Cetuximab Approved Phase 2, Phase 3, Phase 1 205923-56-4 56842117 2333
29
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
30
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
31
Gefitinib Approved, Investigational Phase 3,Phase 2,Phase 1 184475-35-2 123631
32
Trioxsalen Approved Phase 3,Phase 2 3902-71-4 5585
33
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
34
Ondansetron Approved Phase 3 99614-02-5 4595
35
Ranitidine Approved Phase 3 66357-59-3, 66357-35-5 3001055
36
Tegafur Approved, Investigational Phase 3 17902-23-7 5386
37
Trastuzumab Approved, Investigational Phase 3,Phase 2,Phase 1 180288-69-1 9903
38
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
39
Esomeprazole Approved, Investigational Phase 3 161796-78-7, 119141-88-7 9579578 4594
40
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
41 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
42 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
43 Antimitotic Agents Phase 3,Phase 2,Phase 1
44 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
45 Antibodies Phase 3,Phase 2,Phase 1
46 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
47 Immunoglobulins Phase 3,Phase 2,Phase 1
48 Vaccines Phase 3,Phase 2
49 Hematinics Phase 2, Phase 3
50 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 264)

# Name Status NCT ID Phase Drugs
1 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
2 Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer Recruiting NCT02366819 Phase 4 Oxaliplatin;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
3 Combination Chemotherapy in Treating Patients With Esophageal Cancer Unknown status NCT00041262 Phase 3 cisplatin;epirubicin hydrochloride;fluorouracil
4 Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002884 Phase 3 chemotherapy;cisplatin;fluorouracil
5 Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002883 Phase 3 cisplatin;fluorouracil
6 Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer Unknown status NCT00509561 Phase 2, Phase 3 capecitabine;cisplatin
7 Confocal Endomicroscopy for Barrett's Esophagus Completed NCT00487695 Phase 3
8 Surgery With or Without Radiation Therapy and Chemotherapy in Treating Patients With Esophageal Cancer Completed NCT00047112 Phase 3 cisplatin;fluorouracil
9 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Cancer of the Esophagus Completed NCT00002631 Phase 3 chemotherapy;cisplatin;fluorouracil
10 Surgery With or Without Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus Completed NCT00003118 Phase 3 cisplatin;fluorouracil
11 Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer Completed NCT00020787 Phase 3 cisplatin;fluorouracil
12 Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer Completed NCT00861094 Phase 2, Phase 3 cisplatin;5-FU;oxaliplatin;Folinic Acid
13 Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy Completed NCT01243398 Phase 3
14 Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer Completed NCT00978549 Phase 3 docetaxel;steroid therapy
15 Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus Recruiting NCT02509286 Phase 3 5-Fluorouracil;Leucovorin;Oxaliplatin;Docetaxel;Carboplatin;Paclitaxel
16 NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS) Recruiting NCT01726452 Phase 3 Epirubicin;Cisplatin;5 Flourouracil/ Capecitabine;Paclitaxel;Carboplatin
17 Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction Recruiting NCT01523015 Phase 2, Phase 3
18 STRETTA ,Radio Frequency Ablation (RFA) v/s Sham Therapy for the Treatment of Refractory GERD Recruiting NCT02935881 Phase 3
19 A Randomized, Controlled, Multicenter Study to Compare Preoperative Radiochemotherapy With Preoperative Chemotherapy in Patients With Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma Recruiting NCT03013010 Phase 3 Tegafur-Gimeracil-Oteracil Potassium;Oxaliplatin
20 Clinical Study of Time Optimizing of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer Recruiting NCT02628665 Phase 3 photosensitizer(photofrin)
21 Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Active, not recruiting NCT01196390 Phase 3 Carboplatin;Paclitaxel
22 A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia Active, not recruiting NCT00357682 Phase 3 Esomeprazole;Esomeprazole;Aspirin
23 Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery Active, not recruiting NCT01107639 Phase 3 cisplatin;docetaxel
24 Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer Active, not recruiting NCT00052910 Phase 3 cisplatin;epirubicin hydrochloride;fluorouracil;leucovorin calcium
25 Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma Unknown status NCT00964080 Phase 1, Phase 2 MBP-426/Leucovorin/5-FU
26 The Effect of Preoperative Docetaxel, Cisplatin and Capecitabine on Serum RUNX3 Hypermethylation Status in Patients With Gastric and Lower Oesophagus Adenocarcinoma Unknown status NCT00674167 Phase 2 Docetaxel;Cisplatin;Capecitabine
27 Panitumumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Advanced Esophageal or Gastroesophageal Junction Cancer Unknown status NCT01307956 Phase 2 oxaliplatin;leucovorin calcium;fluorouracil
28 Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach Unknown status NCT00601705 Phase 2 cisplatin;epirubicin hydrochloride;fluorouracil;oxaliplatin
29 Tethered Capsule Endoscope in Screening Participants for Barrett Esophagus Unknown status NCT00903136 Phase 1, Phase 2
30 Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus Unknown status NCT00003326 Phase 2 paclitaxel
31 Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer Unknown status NCT00006472 Phase 2 carboplatin;fluorouracil;paclitaxel
32 Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Cancer of the Stomach or Esophagus Unknown status NCT00005607 Phase 2 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
33 Liposomal Doxorubicin in Treating Patients With Advanced Stomach Cancer Unknown status NCT00004236 Phase 2 pegylated liposomal doxorubicin hydrochloride
34 Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery Unknown status NCT00005876 Phase 2 rubitecan
35 Pre-operative Epirubicin, Cisplatin, and Capecitabine in Patients With Newly Diagnosed Localised Oesophageal Adenocarcinoma Completed NCT00220103 Phase 2 epirubicin, capecitabine, cisplatin
36 Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma Completed NCT00583674 Phase 2 AMG 386 placebo;AMG 386 10mg/kg;AMG 386 3mg/kg;Cisplatin;Capecitabine;Cisplatin;Capecitabine;Cisplatin;Capecitabine
37 Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus Completed NCT00259987 Phase 2 Lapatinib (GW572016) oral tablets
38 3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction Completed NCT00077545 Phase 2 triapine;cisplatin
39 Phase II Study of Irinotecan and Panitumumab Completed NCT00836277 Phase 2 Panitumumab;Irinotecan
40 Irinotecan in Treating Patients With Esophageal or Stomach Cancer Completed NCT00003748 Phase 2 irinotecan hydrochloride
41 Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia Completed NCT00591123 Phase 2 FOLFOX and Erlotinib
42 Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer Completed NCT00354679 Phase 2 cisplatin;irinotecan hydrochloride
43 Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction Completed NCT00891878 Phase 2 capecitabine;sunitinib malate
44 Celecoxib, Paclitaxel, and Carboplatin in Treating Patients With Cancer of the Esophagus Completed NCT00066716 Phase 2 carboplatin;celecoxib;paclitaxel
45 Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer Completed NCT00985192 Phase 2 everolimus
46 Combination Chemotherapy After Surgery in Treating Patients With Cancer of the Esophagus or Stomach Completed NCT00003237 Phase 2 cisplatin;paclitaxel
47 Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach Completed NCT00020761 Phase 2 irinotecan hydrochloride;paclitaxel
48 Oxaliplatin and Capecitabine in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer Completed NCT00040859 Phase 2 capecitabine;oxaliplatin
49 Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer Completed NCT00033657 Phase 2 cisplatin;irinotecan hydrochloride;paclitaxel
50 Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer Completed NCT00165490 Phase 2 Cetuximab;Cisplatin;Irinotecan

Search NIH Clinical Center for Esophagus Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma of esophagus

Genetic Tests for Esophagus Adenocarcinoma

Anatomical Context for Esophagus Adenocarcinoma

MalaCards organs/tissues related to Esophagus Adenocarcinoma:

38
Testes, Liver, Colon, Bone

Publications for Esophagus Adenocarcinoma

Articles related to Esophagus Adenocarcinoma:

# Title Authors Year
1
The clinical significance of cysteine dioxygenase type 1 methylation in Barrett esophagus adenocarcinoma. ( 28184414 )
2017
2
Epigenetic regulation on the gene expression signature in esophagus adenocarcinoma. ( 28049580 )
2016
3
Esophagus adenocarcinoma in a young patient with celiac disease; Is celiac disease a predisposing factor for esophagus adenocarcinoma as well as squamous cell carcinoma? ( 26185881 )
2014
4
In vivo molecular imaging of HER2 expression in a rat model of Barrett's esophagus adenocarcinoma. ( 24708360 )
2014
5
Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis. ( 21166737 )
2010
6
Gene expression profiling of esophageal cancer: comparative analysis of Barrett's esophagus, adenocarcinoma, and squamous cell carcinoma. ( 17236199 )
2007
7
Familiality in Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction. ( 16985029 )
2006
8
Meningeal carcinomatosis in patient with esophagus adenocarcinoma. ( 9105327 )
1997

Variations for Esophagus Adenocarcinoma

Expression for Esophagus Adenocarcinoma

Search GEO for disease gene expression data for Esophagus Adenocarcinoma.

Pathways for Esophagus Adenocarcinoma

Pathways related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.93 CDKN2A ERBB2 PTGS2 TP53
2
Show member pathways
11.76 CDKN2A ERBB2 TP53
3 11.49 CDKN2A ERBB2 TP53
4 11 CDKN2A ERBB2 TP53
5 10.71 CDKN2A TP53
6
Show member pathways
10.66 CDKN2A TP53
7 10.66 CDKN2A ERBB2 TP53

GO Terms for Esophagus Adenocarcinoma

Biological processes related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 anterior/posterior axis specification GO:0009948 9.37 CDX1 CDX2
2 replicative senescence GO:0090399 9.32 CDKN2A TP53
3 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.26 ATP12A ATP4A
4 regulation of somitogenesis GO:0014807 9.16 CDX1 CDX2
5 negative regulation of immature T cell proliferation in thymus GO:0033088 8.96 CDKN2A ERBB2
6 response to organonitrogen compound GO:0010243 8.8 CDO1 PTGS2 TP53

Molecular functions related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen GO:0016702 9.16 CDO1 PTGS2
2 sodium:potassium-exchanging ATPase activity GO:0005391 8.96 ATP12A ATP4A
3 hydrogen:potassium-exchanging ATPase activity GO:0008900 8.62 ATP12A ATP4A

Sources for Esophagus Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....